Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-12-04

FDA Approved: JANUMET XR — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for JANUMET XR (sitagliptin and metformin hydrochloride) from Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JANUMET XR (Sitagliptin and metformin hydrochloride)

Snippet

SUPPL AP for JANUMET XR (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE)